Publications by authors named "Rachel S Park"
We evaluated primary tumors from two cohorts, Spain (N = 111) and Greece (N = 102), for patients who were treated with platinum-based chemotherapy. Patients were tested for HER2 status (IHC score of 3+ or FISH ratio of ≥ 2.2) by immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), DNA copy number, mRNA expression, and mutation status in patients with metastatic urothelial carcinoma (UC), and its impact on survival.
View Article and Find Full Text PDFArticle Synopsis
- - FGFR3, often mutated or overexpressed in nonmuscle-invasive urothelial carcinoma, shows differing prevalence in muscle-invasive urothelial carcinoma with about 29% of primary tumors and 49% of metastases displaying FGFR3 protein expression.
- - FGFR3 mutations are relatively rare in both primary (2%) and metastatic (9%) tumors, while mutant tumors reveal significantly higher FGFR3 mRNA levels compared to wild-type tumors.
- - Changes in FGFR3 copy number are infrequent, with 0.8% in primary tumors and 3.0% in metastatic tumors, highlighting that while FGFR3 expression may be present, mutations and copy number variations are not common in muscle
Purpose: Metastatic urothelial carcinoma of the bladder is associated with multiple somatic copy-number alterations (SCNAs). We evaluated SCNAs to identify predictors of poor survival in patients with metastatic urothelial carcinoma treated with platinum-based chemotherapy.
Experimental Design: We obtained overall survival (OS) and array DNA copy-number data from patients with metastatic urothelial carcinoma in two cohorts.